Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients. A Statement from a European Atherosclerosis Society Task Force

This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.

Source: Atherosclerosis - April 12, 2021 Category: Cardiology Authors: Maurizio Averna, Maciej Banach, Eric Bruckert, Heinz Drexel, Michel Farnier, Dan Gaita, Paolo Magni, Winfried M ärz, Luis Masana, Alberto Mello e Silva, Zeljko Reiner, Emilio Ros, Michal Vrablik, Alberto Zambon, Jose L. Zamorano, Jane K. Stock, Lale S. T Tags: From the EAS Source Type: research